Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

35.24
-0.2499-0.70%
Post-market: 35.250.0137+0.04%16:10 EDT
Volume:732
Turnover:25.84K
Market Cap:16.56M
PE:- -
High:35.25
Open:35.25
Low:35.24
Close:35.49
52wk High:37.90
52wk Low:28.87
Shares:469.95K
Float Shares:469.95K
Volume Ratio:1.05
T/O Rate:0.16%
Dividend:0.41
Dividend Rate:1.16%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Contineum Therapeutics, - Johnson & Johnson Continues to Evaluate Trial Data for Jnj-5120/Pipe-307

THOMSON REUTERS
·
Sep 15

NYSE Order Imbalance 99880.0 Shares on Sell Side

THOMSON REUTERS
·
Sep 15

Eli Lilly Stock (LLY) Has 45% Upside, Says Citigroup

TIPRANKS
·
Sep 15

Novo Nordisk is Dropping Some Weight. it Still Faces a Bigger Challenge.

Dow Jones
·
Sep 15

Eli Lilly Exec Says Co NOW Has More than 30% Share in New Starts Within Oral Obesity Treatment Market -Morgan Stanley Conf

THOMSON REUTERS
·
Sep 15

Eli Lilly and Co Stock (LLY) Moved Up by 3.01% on Sep 14: Drivers Behind the Movement

TradingKey
·
Sep 15

Novartis AG Rises Monday, Outperforms Market

Dow Jones
·
Sep 15

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Sep 14

CRO Sector Surges Strongly as Multiple Listed Companies Share Latest Business Updates

Deep News
·
Sep 14

Eli Lilly Announces R$ 0.2 Per Unit Dividend for 3Q 2026 BDRs

Reuters
·
Sep 14

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Sep 14

Hong Kong Stocks Recover as WCLC Conference Sparks Biotech Rally, While US AI Slowdown Calls Raise Questions

Stock News
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Sep 14

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Sep 14

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Sep 14

Healthcare Priorities Over Next Five Years to Target Three Population Groups

Deep News
·
Sep 14

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Sep 14

Market Consolidation with Low Volume: Innovative Drugs Surge Against the Trend, Banking Index Hits New Annual High, Optical Module Leaders Retreat While Capital Seeks Opportunities in High-Optical ETFs

Deep News
·
Sep 14

Immunocore achieves target patient enrollment in TEBE-AM clinical trial

TIPRANKS
·
Sep 14